Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Prevention, Genetics
Results 1-25 of 99 for your search:
Start Over
Behavioral Counseling and Nicotine Replacement Therapy or Varenicline in Helping Smokers Quit
Phase: Phase IV
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Age: 18 to 65
Trial IDs: 2014-0207, NCI-2014-01485, NCT02162849
Varenicline and Nicotine Replacement Therapy for Initial Smoking Cessation and Treatment in Smokers
Phase: Phase IV
Type: Behavioral study, Prevention
Age: 18 to 65
Trial IDs: 2014-0213, NCI-2015-00610, NCT02271919
Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: STUDY00001602, NCI-2015-01331, AD-1310-08709, NCI-2015-00937, NCT02244918
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
Phase: Phase III
Type: Prevention
Age: 15 and over
Trial IDs: GHRT01, NCI-2014-02097, NCT01479283
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: CPP-FAP-310, NCI-2013-01805, NCT01483144
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: AP311736, NCI-2014-01024, NCT01599754
Metformin Hydrochloride with or without Lifestyle Intervention in Preventing Endometrial Cancer in Obese Post-Menopausal Patients with High Insulin Levels
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Age: 50 to 60
Trial IDs: 2011-0739, NCI-2013-00834, NCT01697566
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 116428, NCI-2014-01414, 2012-003438-18, NCT01767467
Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 35 and over
Trial IDs: AMC-A01, NCI-2014-00636, NCT02135419
Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: E-101:PH3:2012:004, NCI-2014-00786, NCT01297959
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: 0113-CL-1004, NCI-2013-01949, 2013-000903-18, NCT01877655
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, 150067, NCT02356159
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: CCSJ148X2201, NCI-2015-00634, NCT02268526
Low-Dose Bortezomib in Preventing Bone Formation in Patients With Smoldering Multiple Myeloma
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: HCI33979, NCI-2010-02379, NCT00983346
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 40 to 120
Trial IDs: MC054A, NCI-2009-01192, 09-001758, NCT01647126, R01-CA-113681, NCT00983580
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 13 to 26
Trial IDs: AMC-072, NCI-2011-02510, CDR0000685816, NCT01209325
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 and over
Trial IDs: 08218, NCI-2010-01976, 115422, NCT01196936
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 11-0265, NCI-2011-01246, NCT01414426
Prevention of Postoperative Pneumonia (POPP)
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: 201106336, NCI-2012-00278, NCT01446874
Dasatinib in Preventing Second Primary Breast Cancer in Women with Estrogen Receptor Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 2010-0794, NCI-2012-00037, KG09 1020, Susan Komen Foundation Grant Number(s): KG09 1020, NCT01471106
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD after Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients with Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 0 to 75
Trial IDs: 2546.00, NCI-2011-03828, NCT01527045
Start Over